Latest news with #D.BoralCapitalLLC
Yahoo
4 days ago
- Business
- Yahoo
Wintergreen Acquisition Corp. Announces the Closing of its Initial Public Offering and Partial Exercise of Underwriter's Over-Allotment Option to Purchase Additional Units
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Wintergreen Acquisition Corp. (NASDAQ: WTGUU) ('Wintergreen' or the 'Company') today announced the closing of its initial public offering of 5,595,000 units. This includes 595,000 units issued pursuant to the underwriter's partial exercise of its over-allotment option, which also closed today, May 30, 2025. The offering was priced at $10.00 per unit, resulting in gross proceeds of $55,950,000. Wintergreen's units are listed on the Nasdaq Capital Market ('NASDAQ') and began trading under the ticker symbol 'WTGUU' on May 29, 2025. Each unit consists of one ordinary share, par value $0.0001 per share, and one right entitling the holder thereof to receive one-eighth (1/8) of one ordinary share upon consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on NASDAQ under the symbols 'WTG' and 'WTGUR,' respectively. Of the proceeds received from the consummation of the initial public offering (including the partial exercise of the over-allotment option) and a simultaneous private placement of 253,875 placement units to the Company's sponsor, MACRO DREAM Holdings Limited, for an aggregate purchase price of $2,538,750, a total of $56,089,875 (or $10.025 per public unit) was placed into a trust account in the United States at Wilmington Trust, National Association. The Company intends to use the net proceeds from the offering to acquire a business focused on the technology, media, and telecommunications industries. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. D. Boral Capital LLC acted as sole book-running manager in the offering. Concord & Sage P.C. served as U.S. legal counsel to Wintergreen on the initial public offering, and Ogier served as Cayman Islands legal counsel to Wintergreen. Robinson & Cole LLP served as legal counsel to D. Boral Capital LLC. A registration statement on Form S-1 (File No. 333-286795) relating to these securities has been filed with the Securities and Exchange Commission ('SEC'), and was declared effective on May 28, 2025. The offering was made by means of a prospectus. Copies of the prospectus may be obtained from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, by phone at +1 (212) 970 5150 or emailing info@ Copies of the registration statement can also be obtained by visiting EDGAR on the SEC's website at No Offer. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Wintergreen Acquisition Corp. Wintergreen Acquisition Corp. is a newly incorporated blank check company incorporated as a Cayman Islands exempted company (company number 409590) for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Source: Wintergreen Acquisition Corp. Contact: Wintergreen Acquisition YaoChief Executive Officer and ChairmanRoom 8326, Block B, Hongxiang Cultural and Creative Industrial Park,90 Jiukeshu West Road, Tongzhou District, Beijing, PRC Wintergreen Acquisition TanCFO008613652371477
Yahoo
6 days ago
- Business
- Yahoo
Wintergreen Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Wintergreen Acquisition Corp. (NASDAQ: WTGUU, the 'Company') announced today that it priced its initial public offering of 5,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Capital Market ('NASDAQ') and trade under the ticker symbol 'WTGUU' beginning on May 29, 2025. Each unit consists of one ordinary share and one right to receive one-eighth (1/8th) of one ordinary share upon consummation of an initial business combination. Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on NASDAQ under the symbols 'WTG' and 'WTGUR,' respectively. The Company intends to use the net proceeds from the offering to acquire a business focused on the technology, media, and telecommunications industries. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. The Company is led by Mr. Yongfang ("Fayer") Yao, its Chief Executive Officer and Chairman, and Mr. Bingzhao Tan, its Chief Financial Officer and Director. The Company's independent directors include Ms. Caihong Chen, Ms. Ru Ding, and Mr. Xiangxiang Wei. D. Boral Capital LLC is acting as sole book-running manager in the offering. The underwriter has been granted a 45-day option to purchase up to an additional 750,000 units offered by the Company to cover over-allotments, if any. The offering is expected to close on May 30, 2025, subject to customary closing conditions. Concord & Sage P.C. and Ogier served as legal counsel to the Company on the initial public offering. Robinson & Cole LLP served as legal counsel to D. Boral Capital LLC. A registration statement on Form S-1 (File No. 333-286795) relating to these securities has been filed with the Securities and Exchange Commission ('SEC'), and was declared effective on May 28, 2025. The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022 or by calling +1 (212) 970 5150 or emailing info@ Copies of the registration statement can also be obtained by visiting EDGAR on the SEC's website at No Offer. The information in the prospectus and this press release is not complete and may be changed. The prospectus and this press release are not offers to sell these securities and are not soliciting an offer to buy these securities in any state where such offer or sale is not permitted. About Wintergreen Acquisition Corp. Wintergreen Acquisition Corp. is a newly incorporated blank check company incorporated as a Cayman Islands exempted company (company number 406731) for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. Its search for a target business will focus on companies with operations or prospective operations in the Asia Pacific region, including the Greater China region, that have advanced and highly differentiated solutions. Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Source: Wintergreen Acquisition Corp. Contact: Bingzhao TanCFO Wintergreen Acquisition Corp. 008613652371477
Miami Herald
16-05-2025
- Business
- Miami Herald
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the "Offering") of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol "APUS." D. Boral Capital LLC ("D. Boral") acted as sole bookrunner for the Offering. D. Boral was represented by Blank Rome LLP, led by Brad Shiffman and Naomi Gallimore. Apimeds was represented by Nelson Mullins Riley & Scarborough LLP, led by David Mannheim, Mike Bradshaw and Kathryn Simons. The Company expects to use the net proceeds from the sale of the shares to fund a Phase III clinical trial in knee osteoarthritis, to initiate at least one non-registered corporate sponsorship study in multiple sclerosis, to manufacture its product candidate, and to address general working capital needs. A registration statement on Form S-1 (File No. 333-282324) relating to the securities sold in the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on February 11, 2025. A post-effective amendment to the registration statement was filed with the SEC and declared effective on May 5, 2025. This Offering was made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained, when available, from: D. Boral Capital LLC, 590 Madison Ave., 39th Floor, New York, NY 10022, by telephone: (212) 970-5150, or by email at: info@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Apimeds Pharmaceuticals US, Inc. Apimeds (NYSE:APUS) is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who fail to respond adequately to conservative non-pharmacologic therapy and simple analgesics. For more information visit About D. Boral Capital D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America. A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $30 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products. Forward-Looking Statements This press release contains statements that constitute "forward-looking statements," with respect to the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the Offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in "Special Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the documents that referred to in the prospectus filed with the SEC with the understanding that the Company's future results may be materially different from and worse than what we expect. Copies are available on the SEC's website, Other sections of the prospectus include additional factors which could adversely impact the Company's business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company's management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements. For more information, please contact: D. Boral Capital LLCEmail: info@ +1(212)-970-5150 SOURCE: D. Boral Capital
Yahoo
16-05-2025
- Business
- Yahoo
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering
NEW YORK CITY, NY / / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the "Offering") of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol "APUS." D. Boral Capital LLC ("D. Boral") acted as sole bookrunner for the Offering. D. Boral was represented by Blank Rome LLP, led by Brad Shiffman and Naomi Gallimore. Apimeds was represented by Nelson Mullins Riley & Scarborough LLP, led by David Mannheim, Mike Bradshaw and Kathryn Simons. The Company expects to use the net proceeds from the sale of the shares to fund a Phase III clinical trial in knee osteoarthritis, to initiate at least one non-registered corporate sponsorship study in multiple sclerosis, to manufacture its product candidate, and to address general working capital needs. A registration statement on Form S-1 (File No. 333-282324) relating to the securities sold in the Offering was filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on February 11, 2025. A post-effective amendment to the registration statement was filed with the SEC and declared effective on May 5, 2025. This Offering was made only by means of a prospectus. Copies of the final prospectus relating to the Offering may be obtained, when available, from: D. Boral Capital LLC, 590 Madison Ave., 39th Floor, New York, NY 10022, by telephone: (212) 970-5150, or by email at: info@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Apimeds Pharmaceuticals US, Inc. Apimeds (NYSE:APUS) is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects. Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who fail to respond adequately to conservative non-pharmacologic therapy and simple analgesics. For more information visit About D. Boral Capital D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America. A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately $30 billion in capital since its inception in 2020, executing ~350 transactions across a broad range of investment banking products. Forward-Looking Statements This press release contains statements that constitute "forward-looking statements," with respect to the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the Offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "likely to" or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in "Special Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the documents that referred to in the prospectus filed with the SEC with the understanding that the Company's future results may be materially different from and worse than what we expect. Copies are available on the SEC's website, Other sections of the prospectus include additional factors which could adversely impact the Company's business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company's management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements. For more information, please contact: D. Boral Capital LLCEmail: info@ +1(212)-970-5150 SOURCE: D. Boral Capital View the original press release on ACCESS Newswire
Associated Press
04-03-2025
- Business
- Associated Press
D. Boral Capital Acted as Joint Bookrunner to LZ Technology Holdings Limited (Nasdaq: LZMH) in Connection with its $7.2 Million Initial Public Offering
NEW YORK CITY, NY / ACCESS Newswire / March 4, 2025 / On Feb. 28, 2025, LZ Technology Holdings Limited (NASDAQ:LZMH) ('LZ Technology' or the 'Company'), an information technology and advertising company, announced the successful closing of its initial public offering of 1,800,000 Class B ordinary shares, par value $0.000025 per share (the 'Class B Ordinary Shares'), at a public offering price of $4.00 per share. The offering generated total gross proceeds of approximately $7.2 million, before deducting underwriting discounts and other offering expenses. The Company's Class B Ordinary Shares started trading on the Nasdaq Capital Market on February 27, 2025 under the ticker symbol 'LZMH.' In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 270,000 Class B Ordinary Shares at the public offering price, less underwriting discounts. LZ Technology intends to use the net proceeds from this offering for research and development, international expansions, strategic acquisitions, marketing efforts and working capital. The offering was conducted on a firm commitment basis. Benjamin Securities, Inc. and D. Boral Capital LLC acted as underwriters for the offering (the 'Underwriters'). Bevilacqua PLLC acted as U.S. securities counsel to the Company, and Hunter Taubman Fischer & Li LLC acted as U.S. securities counsel to the Underwriters in connection with the offering. A registration statement on Form F-1 (File No. 333-276234) relating to the offering, as amended, has been filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective by the SEC on February 26, 2025. The offering was made only by means of a prospectus, forming part of the registration statement. You may get these documents for free by visiting EDGAR on the SEC Web site at Alternatively, copies of the final prospectus relating to the offering may be obtained from Benjamin Securities, Inc. by email at [email protected], by standard mail to 3 West Garden Street, Suite 407, Pensacola, FL 32502, or by telephone at +1 (516) 931-1090; or from D. Boral Capital LLC by standard mail to D. Boral Capital LLC, 590 Madison Ave 39th Floor, New York, NY 10022, or by email at [email protected], or by telephone at +1(212)-970-5150. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. About LZ Technology Holdings Limited LZ Technology Holdings Limited is an information technology and advertising company operating through its subsidiaries in China. The Company's business spans three key verticals: Smart Community, Out-of-Home Advertising, and Local Life. Its Smart Community services provide intelligent access control and safety management systems, installed in thousands of residential communities in China. Its Out-of-Home Advertising division offers multi-channel advertising solutions through a vast network of monitors across approximately 120 cities in China, with ad placements on access control screens, SaaS platforms, and third-party advertising spaces. The Company's Local Life vertical connects businesses with consumers through online promotions, social media marketing, and retail sales of various products and services. LZ Technology is committed to providing high-quality services to communities and businesses. About D. Boral Capital D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the UAE, and Latin America. A recognized leader on Wall Street, D. Boral Capital has successfully aggregated over $23 billion in capital since its inception in 2020, executing approximately 300 transactions across a broad range of investment banking products. Forward-Looking Statement Certain statements in this press release are 'forward-looking statements' as defined under the federal securities laws, including, but not limited to, the Company's statements regarding the use of proceeds from the sale of the Company's shares in the offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as 'believe', 'plan', 'expect', 'intend', 'should', 'seek', 'estimate', 'will', 'aim' and 'anticipate', or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. D. Boral Capital LLC
